Trinity Biotech, a key player in human diagnostics and diabetes management solutions, has just unveiled its groundbreaking new product, CGM+. This isn't just another continuous glucose monitoring (CGM) system; it's an AI-native wearable biosensor platform designed to tap into the booming $260 billion AI wearables market.
What makes CGM+ stand out is its comprehensive approach to health monitoring. Unlike traditional CGMs that focus solely on glucose, CGM+ integrates an ultra-thin, minimally invasive electrochemical glucose sensor with continuous monitoring of heart activity, body temperature, and physical activity. All of this data is collected within a single, sleek, and user-friendly modular device. This multi-sensor data stream is specifically optimized for real-time AI analysis, aiming to provide a much deeper and more contextual understanding of an individual's metabolic and physiological health. Trinity Biotech believes these expanded data points are crucial for gaining insights into essential metabolic factors like sleep, stress, and physical activity.
Trinity Biotech's vision for CGM+ is to bridge the gap between medical-grade monitoring and consumer wellness insights. Their proprietary needle-free glucose sensor technology not only facilitates the collection of these diverse data points from one device, but it also significantly reduces the number of disposable components and waste, leading to a lower cost of care compared to current market leaders.
John Gillard, CEO of Trinity Biotech, emphasizes that CGM+ is more than just a device; it's a "proprietary data engine for the AI health ecosystem." He believes this technology will power the next wave of personalized, predictive, and preventative care, opening up entirely new commercial avenues for the company, from device sales to AI-driven data services. It positions Trinity Biotech to compete beyond traditional diagnostics, at the intersection of chronic disease management, digital health, and consumer wellness.
As healthcare increasingly shifts towards precision medicine and continuous real-world data collection, CGM+ is positioned to be a critical enabler of AI-based diagnostics, behavioral coaching, and chronic disease management. With its commercial launch anticipated in mid-2026, Trinity Biotech expects multiple revenue streams, including device sales, AI analytics subscriptions, and strategic partnerships with healthcare providers, insurers, and digital health platforms. The company recently completed a pre-pivotal trial of its upgraded glucose sensor technology, with key findings expected to be released soon, further solidifying its promising future in the intelligent wearables market.